METHYLERGONOVINE MALEATE


Trade Names	METHERGINE METHYLERGONOVINE MALEATE
Synonyms	Methergine Methylergometrine maleate Methylergonovine maleate Methylergonovinium bimaleate NSC-757104
Status
Molecule Category	Mixture
UNII	IR84JPZ1RK


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	NOFOWWRHEPHDCY-DAUURJMHSA-N
Smiles	CC[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1.O=C(O)/C=C\C(=O)O
InChI	InChI=1S/C20H25N3O2.C4H4O4/c1-3-14(11-24)22-20(25)13-7-16-15-5-4-6-17-19(15)12(9-21-17)8-18(16)23(2)10-13;5-3(6)1-2-4(7)8/h4-7,9,13-14,18,21,24H,3,8,10-11H2,1-2H3,(H,22,25);1-2H,(H,5,6)(H,7,8)/b;2-1-/t13-,14+,18-;/m1./s1

Pharmacology

Mechanism of Action	Action	Reference
Dopamine D1 receptor antagonist	ANTAGONIST	PubMed PubMed Wikipedia


Protein: Dopamine D1 receptor Description: D(1A) dopamine receptor Organism : Homo sapiens P21728 ENSG00000184845











Protein: Serotonin 2b (5-HT2b) receptor Description: 5-hydroxytryptamine receptor 2B Organism : Homo sapiens P41595 ENSG00000135914

Cross References

Resources	Reference
ChEBI	6874
ChEMBL	CHEMBL1200843
FDA SRS	IR84JPZ1RK
Guide to Pharmacology	150
KEGG	D08207
PubChem	5281072
SureChEMBL	SCHEMBL239437
ZINC	ZINC39949130

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).